



PRESS RELEASE – FOR IMMEDIATE RELEASE

**IntegraGen, Gustave Roussy, INSERM and Sogeti High Tech Announce Collaborative Development of an Advanced Scientific Software Program to Assist with the Interpretation of Genome Sequencing Data for Cancer Patients**

*The Interpretation of Clinical Exome (ICE) Project will be supported by the French State and the Regions through the 17th Single Interministerial Fund (FUI)*

---

**EVRY, VILLEJUIF, PARIS, France, June 19, 2014** - IntegraGen, a French leader in genomics services also specializing in the development of molecular diagnostic tests for oncology and autism, Gustave Roussy, the leading European center in the fight against cancer in Europe, Sogeti High Tech, a 100% subsidiary of the Capgemini Group, and INSERM today announced the launch of the Interpretation of Clinical Exome (ICE) Project, a collaborative project for developing an advanced scientific software program that will support data interpretation of genome sequencing performed for cancer patients. The objective of the ICE Project is to optimize the diagnosis of cancer patients and to develop a data driven approach for identifying targeted treatment options for these patients.

The ICE Project, which will be led by IntegraGen, was selected as part of the call for proposals for the 17th Single Interministerial Fund (Fonds Unique Interministériel). The total amount of funding awarded for the project was €2.2 million. The four project partners bring unique experiences in oncology, sequencing, data management, software development and clinical interpretation of sequencing data. As a result of this funding, the partners anticipate the rapid development of the first version of this software tool. The total annual worldwide market for new software tools which interpret clinical sequencing data is estimated to be several billion euros by 2016.

"The exponential growth in the availability of sequencing data from the tumors of cancer patients makes it essential to develop tools that permits the isolation of patient specific data with the associated identification of information which impacts the clinical care of patients," stated Professor Eric Solary, Research Director, Gustave Roussy, and Director of Inserm Unit 1009, Normals and Pathologies Haematopoiesis. "Access to sequencing data of all coding genes of a patient requires a thorough review of the sequencing results and automated assistance its interpretation, otherwise the data will not be usable or compatible with the timely management of cancer patients."

"The development of scientific software tools which add high value and benefit the industrial sector of Life Sciences is a strategic area for Sogeti High Tech," said Dominique Lafond, CEO of Sogeti High Tech, a subsidiary of the Capgemini Group and center of excellence in engineering and technology consulting. "We are excited to bring our expertise to our Big Data partners for the ICE Project which includes French and European leaders in cancer research and genomic sequencing."

"Genomic sequencing has been revolutionized by the advent of newer technologies that utilize massively parallel sequencing in order to greatly reduce the cost and time of data generation. As a result, the bottleneck is now the management of tens of gigabytes of data that represent the exome and transcriptome of a patient's tumor. The ICE Project will allow clinicians to treat patients according to the biological characteristics of their tumor," said Bernard Courtieu, Chairman and CEO of IntegraGen. "For IntegraGen, this project represents a new stage in the development of an

integrated process for clinical genomics and a major contribution to the Cancer Plan III announced by the French Government last April.

The partners for the ICE Project plan to finalize a first version of the software tool in 2016, and with the development of this tool, support the creation of new jobs and related activities in France.

#### **ABOUT INTEGRAGEN**

Founded in 2000, IntegraGen (ALINT.PA) is a biotechnology company focused on the development and commercialization of molecular diagnostic tests in the fields of autism and oncology. IntegraGen's mission is to translate molecular research into clinical practice through the identification of novel genetic biomarkers and the subsequent development of molecular diagnostic tests which allow clinicians to better manage the clinical care of their patients. IntegraGen is also a leader in delivering expert genomic service solutions to academic researchers and life sciences companies as a result of its scientific knowledge and technological expertise related to cutting edge genomic platforms and bioinformatics.

IntegraGen had total revenues annual of € 5.4 million for 2013. Headquartered in Evry Genopole, IntegraGen had 32 employees as of December 31, 2013. The Company also has a U.S. subsidiary, IntegraGen Inc., based in Cambridge, Massachusetts. IntegraGen is listed on Alternext of Euronext Paris (ISIN: FR0010908723 - Ticker: ALINT - Eligible PEA-SME)

For more information on IntegraGen visit [www.integragen.com](http://www.integragen.com).

#### **ABOUT INSERM**

Founded in 1964, the French National Health and Medical Research Institute (Inserm,) is a public science and technology institute, jointly supervised by the French Ministry of Higher Education and Research and the Ministry of Health. The mission of its scientists is to study all diseases, from the most common to the rarest, through their work in biological, medical and public health research. With a budget of 953 million euros in 2012, Inserm supports more than 300 laboratories across France. In total, the teams include nearly 13,000 researchers, engineers, technicians and administrative staff, etc. Inserm is a member of the National Alliance for Life and Health Sciences, founded in April 2009 with CNRS, Inserm, the CEA, INRA, INRIA, the IRD, the Pasteur Institute, the Conference of University Presidents - Conférence des Présidents d'Université (CPU) and the Conference of Chairmen of The Regional and University Hospital Centres - Conférence des directeurs généraux de centres hospitaliers régionaux and universitaires. This alliance forms part of the policy to reform the research system by better coordinating the parts played by those involved and by strengthening the position of French research in this field through a concerted plan.

In 2014 Inserm is celebrating its 50th anniversary. To mark its 50th anniversary Inserm has decided to deliver its key messages at around a hundred events which will take place all over France and involve all its staff, partners and supervisory bodies throughout the year.

For more information on Inserm visit [www.inserm.fr](http://www.inserm.fr)

#### **ABOUT GUSTAVE ROUSSY**

Gustave Roussy, the leading center in fight against cancer in Europe, is a patient-dedicated center with global expertise against cancer. The center employs 2,630 professionals who work in patient care, research and teaching capacities. Gustave Roussy (2013 figures) has 356 beds and 89 day places and saw 47,000 patients with 11,200 primary consultants. The center is conducting 366 clinical studies with 3,690 patients participating in a clinical trial and 321 patients enrolled in early Phase I trials; 88 patients in early Phase I/II trials .

For more information about Gustave Roussy visit [www.gustaveroussy.fr](http://www.gustaveroussy.fr).

## ABOUT SOGETI HIGH TECH

Sogeti High Tech is a leading company in Engineering and Technology Consulting services. With more than 20 years of expertise of more than 20 years, we undertake major technical and engineering innovation projects for the R&D department of global industrial firms.. To meet our Customers' requirements, we have developed five business lines: Consulting, Systems Engineering, Physics Engineering Software Engineering and Testing.

For more information about Sogeti High Tech visit [www.sogeti-hightech.fr](http://www.sogeti-hightech.fr).

Follow us on Twitter: @ SogetiHighTech1

## CONTACTS

### INTEGRAGEN

Bernard COURTIEU  
President and Chief Executive Officer

Laurence RIOT LAMOTTE  
Chief Financial Officer  
[contact@integragen.com](mailto:contact@integragen.com)  
Tel. : +33 (0)1 60 91 09 00



### NEWCAP.

#### Investor and Medical Relations

Emmanuel HUYNH  
Louis-Victor DELOUVRIER  
[integragen@newcap.fr](mailto:integragen@newcap.fr)  
Tel. : +33 (0)1 44 71 94 94

### GUSTAVE ROUSSY

Christine LASCOMBE  
Director of Communications  
[christine.lascombe@gustaveroussy.fr](mailto:christine.lascombe@gustaveroussy.fr)  
Tel : +33 (0)1 42 11 41 75

Virginie RENVERSADE  
Media Relations Officer  
Tel : +33 (0)1 42 11 50 59 or +33 (0)6 17 66 00 26  
[virginie.renversade@gustaveroussy.fr](mailto:virginie.renversade@gustaveroussy.fr)

### SOGETI HIGH TECH

Philippe MELEARD  
Communications and Marketing Director  
[philippe.meleard@sogeti.com](mailto:philippe.meleard@sogeti.com)  
Tel. : +33 (0)1 40 93 73 23